Development and Validation of a Fully GMP-Compliant Process for Manufacturing Stromal Vascular Fraction: A Cost-Effective Alternative to Automated Methods
Open Access
- 24 September 2020
- Vol. 9 (10), 2158
- https://doi.org/10.3390/cells9102158
Abstract
The therapeutic use of adipose-derived stromal vascular fraction (SVF) is expanding in multiple pathologies. Various processes have been proposed for manufacturing SVF but they must be revisited based on advanced therapy medicinal product (ATMP) regulations. We report here the development and validation of a fully good manufacturing practices (GMP)-compliant protocol for the isolation of SVF. Adipose tissue was collected from healthy volunteers undergoing lipoaspiration. The optimal conditions of collagenase digestion and washing were determined based on measurements of SVF cell viability, yield recovery, and cell subset distribution. Comparability of the SVF obtained using the newly developed manufacturing process (n = 6) and the Celution-based automated method (n = 33), used as a reference, was established using inter-donor analyses. Characteristics of SVF (n = 5) generated using both manufacturing protocols were analyzed for an intra-donor comparison. In addition, these comparisons also included the determination of colony-forming unit fibroblast frequency, in vitro angiogenic activity, and in vivo regenerative effects in a mouse ischemic cutaneous wound model. We successfully developed a process for the generation of SVF presenting higher cell viability and yield recovery compared to the Celution device-based protocol. Characteristics of the SVF including phenotype, capacity for angiogenesis, and wound-healing promotion attested to the comparability of the two manufacturing processes. We validated an optimized non-automated process that should allow for a GMP-compliant, more affordable, and reduced-cost strategy to exploit the potential of SVF-based regenerative therapies.This publication has 54 references indexed in Scilit:
- Clonogenic multipotent stem cells in human adipose tissue differentiate into functional smooth muscle cellsProceedings of the National Academy of Sciences of the United States of America, 2006
- Novel Autologous Cell Therapy in Ischemic Limb Disease Through Growth Factor Secretion by Cultured Adipose Tissue–Derived Stromal CellsArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Immunophenotype of Human Adipose-Derived Cells: Temporal Changes in Stromal-Associated and Stem Cell–Associated MarkersThe International Journal of Cell Cloning, 2005
- Quantitative and reproducible murine model of excisional wound healingWound Repair and Regeneration, 2004
- Secretion of Angiogenic and Antiapoptotic Factors by Human Adipose Stromal CellsCirculation, 2004
- Plasticity of Human Adipose Lineage Cells Toward Endothelial CellsCirculation, 2004
- Yield of human adipose-derived adult stem cells from liposuction aspiratesCytotherapy, 2004
- Human Adipose Tissue Is a Source of Multipotent Stem CellsMolecular Biology of the Cell, 2002
- Chondrogenic Potential of Adipose Tissue-Derived Stromal Cells in Vitro and in VivoBiochemical and Biophysical Research Communications, 2002
- Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based TherapiesTissue Engineering, 2001